Developing and Commercializing Innovative Vaccines
Protecting The World Against Infectious Diseases
Utilizing Proven Innovative Adjuvant Technology
COVID-19 Information and Resources
During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability; and supporting efforts to develop a COVID-19 vaccine.
